πŸ‡ΊπŸ‡Έ FDA
Patent

US 11826315

STAT3 inhibitors

granted A61KA61K31/18A61P

Quick answer

US patent 11826315 (STAT3 inhibitors) held by Tvardi Therapeutics, Inc. expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Tvardi Therapeutics, Inc.
Grant date
Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
11
CPC classes
A61K, A61K31/18, A61P, A61P11/00, A61P25/00